Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.

Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I, Reddy JC.

Clin Cancer Res. 2012 Dec 1;18(23):6509-18. doi: 10.1158/1078-0432.CCR-12-1796. Epub 2012 Oct 2.

2.

Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.

Cirrone F, Harris CS.

Clin Ther. 2012 Oct;34(10):2039-50. doi: 10.1016/j.clinthera.2012.08.011. Epub 2012 Oct 1. Review.

PMID:
23036338
3.

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Review.

PMID:
24259609
4.

A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.

Erdem GU, Sendur MA, Ozdemir NY, Yazıcı O, Zengin N.

Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17. Review.

PMID:
25690490
5.

Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.

De Smaele E, Ferretti E, Gulino A.

Curr Opin Investig Drugs. 2010 Jun;11(6):707-18. Review.

PMID:
20496266
7.

Vismodegib for the treatment of basal cell skin cancer.

Poggi L, Kolesar JM.

Am J Health Syst Pharm. 2013 Jun 15;70(12):1033-8. doi: 10.2146/ajhp120311. Review.

PMID:
23719880
8.

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.

Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R.

Oncologist. 2016 Oct;21(10):1218-1229. Epub 2016 Aug 10. Review.

9.

Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.

Fife K, Herd R, Lalondrelle S, Plummer R, Strong A, Jones S, Lear JT.

Future Oncol. 2017 Jan;13(2):175-184. Epub 2016 Sep 19. Review.

PMID:
27640448
10.

Amenorrhea secondary to a vismodegib-induced blockade of follicle-stimulating hormone-receptor activation.

Strasswimmer J, Latimer B, Ory S.

Fertil Steril. 2014 Aug;102(2):555-7. doi: 10.1016/j.fertnstert.2014.04.045. Epub 2014 Jun 2. Review.

PMID:
24890268
11.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

12.

Maintenance chemotherapy for ovarian cancer.

Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D.

Cochrane Database Syst Rev. 2010 Sep 8;(9):CD007414. doi: 10.1002/14651858.CD007414.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;6:CD007414.

PMID:
20824860
13.

Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.

Ash MM, Jolly PS.

Int J Dermatol. 2015 Mar;54(3):370-4. doi: 10.1111/ijd.12543. Epub 2014 Jul 11. Review.

PMID:
25039741
14.

Interval debulking surgery for advanced epithelial ovarian cancer.

Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006014. doi: 10.1002/14651858.CD006014.pub5. Review. Update in: Cochrane Database Syst Rev. 2013;4:CD006014.

PMID:
20927744
15.

Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.

Lyons TG, O'Kane GM, Kelly CM.

Expert Opin Drug Saf. 2014 Aug;13(8):1125-32. doi: 10.1517/14740338.2014.939952. Review.

PMID:
25033383
16.

Sorafenib for the treatment of advanced renal cell carcinoma.

Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R.

Clin Cancer Res. 2006 Dec 15;12(24):7271-8. Review.

17.

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

Calzavara Pinton P, Licitra L, Peris K, Santoro A, Ascierto PA.

Future Oncol. 2015;11(9):1429-35. doi: 10.2217/fon.15.20. Review.

PMID:
25952787
18.

Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma.

Cox KF, Margo CE.

Cancer Control. 2016 Apr;23(2):133-9. Review.

PMID:
27218790
19.

Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience.

Alfieri S, Bergamini C, Granata R, Locati L, Licitra L, Bossi P.

Target Oncol. 2018 Apr;13(2):253-256. doi: 10.1007/s11523-017-0545-y. Review.

PMID:
29235062

Supplemental Content

Support Center